首页 | 本学科首页   官方微博 | 高级检索  
     


Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre,open-label,phase 2 trial
Authors:Jeffrey A Jones  Anthony R Mato  William G Wierda  Matthew S Davids  Michael Choi  Bruce D Cheson  Richard R Furman  Nicole Lamanna  Paul M Barr  Lang Zhou  Brenda Chyla  Ahmed Hamed Salem  Maria Verdugo  Rod A Humerickhouse  Jalaja Potluri  Steven Coutre  Jennifer Woyach  John C Byrd
Affiliation:1. Division of Pharmaceutics, College of Pharmacy, Columbus, OH, USA;2. The Ohio State University, Columbus, OH, USA;3. Center for Chronic Lymphocytic Leukemia, University of Pennsylvania, Philadelphia, PA, USA;4. University of Texas MD Anderson Cancer Center, Houston, TX, USA;5. Dana-Farber Cancer Institute, Boston, MA, USA;6. UC San Diego Moores Cancer Center, San Diego, CA, USA;g. Georgetown University Hospital, Washington, DC, USA;h. Weill Cornell Medicine, New York, NY, USA;i. Columbia University Medical Center, New York, NY, USA;j. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA;k. AbbVie, North Chicago, IL, USA;l. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt;m. Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA
Abstract:
Keywords:Correspondence to: Prof John C Byrd   Division of Hematology   Department of Medicine   The Ohio State University   Columbus   OH 43210   USA
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号